Cellectis (France) Performance
| ALCLS Stock | EUR 1.73 0.02 1.17% |
The firm shows a Beta (market volatility) of 0.34, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Cellectis' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cellectis is expected to be smaller as well. At this point, Cellectis has a negative expected return of -0.26%. Please make sure to confirm Cellectis' value at risk, as well as the relationship between the daily balance of power and price action indicator , to decide if Cellectis performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cellectis has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
| Begin Period Cash Flow | 241.1 M | |
| Total Cashflows From Investing Activities | 7.3 M |
Cellectis |
Cellectis Relative Risk vs. Return Landscape
If you would invest 207.00 in Cellectis on August 26, 2024 and sell it today you would lose (34.00) from holding Cellectis or give up 16.43% of portfolio value over 90 days. Cellectis is generating negative expected returns and assumes 1.7642% volatility on return distribution over the 90 days horizon. Simply put, 15% of stocks are less volatile than Cellectis, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Cellectis Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cellectis' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cellectis, and traders can use it to determine the average amount a Cellectis' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1452
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALCLS |
Estimated Market Risk
| 1.76 actual daily | 15 85% of assets are more volatile |
Expected Return
| -0.26 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cellectis is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cellectis by adding Cellectis to a well-diversified portfolio.
Cellectis Fundamentals Growth
Cellectis Stock prices reflect investors' perceptions of the future prospects and financial health of Cellectis, and Cellectis fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cellectis Stock performance.
| Return On Equity | -0.56 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (6.01) % | |||
| Current Valuation | 78.42 M | |||
| Shares Outstanding | 55.59 M | |||
| Price To Earning | (14.84) X | |||
| Price To Book | 0.77 X | |||
| Price To Sales | 4.34 X | |||
| Revenue | 57.29 M | |||
| EBITDA | (92.29 M) | |||
| Cash And Equivalents | 47.91 M | |||
| Cash Per Share | 9.93 X | |||
| Total Debt | 91.56 M | |||
| Debt To Equity | 8.20 % | |||
| Book Value Per Share | 3.00 X | |||
| Cash Flow From Operations | (104.56 M) | |||
| Earnings Per Share | (2.13) X | |||
| Total Asset | 382.08 M | |||
| Retained Earnings | (194 M) | |||
| Current Asset | 305 M | |||
| Current Liabilities | 66 M | |||
About Cellectis Performance
Assessing Cellectis' fundamental ratios provides investors with valuable insights into Cellectis' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Cellectis is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is based in Paris, France. CELLECTIS operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 161 people.Things to note about Cellectis performance evaluation
Checking the ongoing alerts about Cellectis for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cellectis help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cellectis generated a negative expected return over the last 90 days | |
| Cellectis may become a speculative penny stock | |
| The company reported the revenue of 57.29 M. Net Loss for the year was (114.2 M) with profit before overhead, payroll, taxes, and interest of 34.18 M. | |
| Cellectis has accumulated about 47.91 M in cash with (104.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Cellectis' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cellectis' stock is overvalued or undervalued compared to its peers.
- Examining Cellectis' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cellectis' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cellectis' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cellectis' stock. These opinions can provide insight into Cellectis' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.